CMS finalized Transparency in Coverage updates as a researcher warns ghost rates and missing inpatient data limit payer price files.
|Articles|July 17, 2012
Groups to CMS: Slow Down
Advertisement
Is the push to change how “dual eligibles” get their health care going too far, too fast?
That’s a question that’s beginning to be heard from lots of quarters — including the Medicare Payment Advisory Commission, the American Medical Association, some analysts and now at least one key lawmaker.
Read the full story:
Source: Politico
Advertisement
Related to this article
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
Bumetanide nasal spray is bioequivalent to oral bumetanide in 68 healthy adults; Esperion is targeting heart failure care before a 2027 CMS payment model.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Leukemia survivors given high-risk ALL therapy had hip bone density about 90% of matched controls, without the partial normalization seen in other groups.
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
Sacral neuromodulation is still considered the gold standard for refractory overactive bladder, with tibial nerve stimulation a less invasive option.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
3
Sacral Neuromodulation Still Seen as OAB Gold Standard in Review
4
FDA Approves First Symptomatic Dermographism Treatment
5